JP6777794B1 - Composition for promoting collagen production - Google Patents
Composition for promoting collagen production Download PDFInfo
- Publication number
- JP6777794B1 JP6777794B1 JP2019125060A JP2019125060A JP6777794B1 JP 6777794 B1 JP6777794 B1 JP 6777794B1 JP 2019125060 A JP2019125060 A JP 2019125060A JP 2019125060 A JP2019125060 A JP 2019125060A JP 6777794 B1 JP6777794 B1 JP 6777794B1
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- rose
- extract
- gly
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000037319 collagen production Effects 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000001737 promoting effect Effects 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 63
- HVIBGVJOBJJPFB-OFQRNFBNSA-N Gly-Pro-Hyp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)C(O)CC1 HVIBGVJOBJJPFB-OFQRNFBNSA-N 0.000 claims abstract description 33
- 108010017349 glycyl-prolyl-hydroxyproline Proteins 0.000 claims abstract description 32
- 241000220222 Rosaceae Species 0.000 claims abstract description 31
- 235000004789 Rosa xanthina Nutrition 0.000 claims abstract description 28
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 claims abstract description 27
- 241000196324 Embryophyta Species 0.000 claims abstract description 26
- 235000011449 Rosa Nutrition 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 241000220317 Rosa Species 0.000 claims description 32
- 235000000539 Rosa canina Nutrition 0.000 claims description 6
- 240000008530 Rosa canina Species 0.000 claims description 6
- 235000011402 Rosa x damascena Nutrition 0.000 claims description 6
- 235000010337 Rosa dumalis Nutrition 0.000 claims description 5
- 235000000542 Rosa eglanteria Nutrition 0.000 claims description 4
- 244000181066 Rosa eglanteria Species 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 240000004978 Rosa x damascena Species 0.000 claims 1
- 230000001133 acceleration Effects 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 description 41
- 108010035532 Collagen Proteins 0.000 description 41
- 229920001436 collagen Polymers 0.000 description 41
- 238000012360 testing method Methods 0.000 description 27
- 102000012422 Collagen Type I Human genes 0.000 description 22
- 108010022452 Collagen Type I Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000605 extraction Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 244000181025 Rosa gallica Species 0.000 description 8
- 239000007640 basal medium Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000002301 combined effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- -1 Pro-Hyp-Gly Chemical compound 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000000533 Rosa gallica Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101150102561 GPA1 gene Proteins 0.000 description 2
- 101150077323 GPA2 gene Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LDWBQGACJJOIKA-RHEFHGCGSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O LDWBQGACJJOIKA-RHEFHGCGSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- QEDRTIXTEAXNMY-XVMARJQXSA-N 2-[[(2s,4r)-1-[(2s)-2-aminopropanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetic acid Chemical compound C[C@H](N)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(O)=O QEDRTIXTEAXNMY-XVMARJQXSA-N 0.000 description 1
- WFDSWNXTPKLLOT-UHNVWZDZSA-N 2-[[(2s,4r)-4-hydroxypyrrolidin-1-ium-2-carbonyl]amino]acetate Chemical compound O[C@H]1CN[C@H](C(=O)NCC(O)=O)C1 WFDSWNXTPKLLOT-UHNVWZDZSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- ZJQXGJBINIMBOY-UHNVWZDZSA-N Gly-Hyp Chemical compound NCC(=O)N1C[C@H](O)C[C@H]1C(O)=O ZJQXGJBINIMBOY-UHNVWZDZSA-N 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000016588 Rosa centifolia Nutrition 0.000 description 1
- 241000914160 Rosa x centifolia Species 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 108010079596 glycyl-4-hydroxyproline Proteins 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010050297 hydroxyprolyl-glycine Proteins 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010028869 lysyl-threonyl-threonyl-lysyl-serine Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940043175 silybin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【課題】コラーゲン産生促進用組成物を提供すること。【解決手段】バラ科バラ属の植物の花弁及び/又はつぼみのエキスと、Gly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドを有効成分として含有するコラーゲン産生促進用組成物。【選択図】図1PROBLEM TO BE SOLVED: To provide a composition for promoting collagen production. SOLUTION: For promoting collagen production containing an extract of petals and / or buds of a plant belonging to the genus Rosa in the family Rosaceae and two types of tripeptides having sequences of Gly-Pro-Hyp and Gly-Pro-Ala as active ingredients. Composition. [Selection diagram] Fig. 1
Description
本発明は、生体のコラーゲン産生を促進するための新規な組成物に関する。 The present invention relates to a novel composition for promoting collagen production in a living body.
コラーゲンは線維芽細胞から細胞外に分泌されるタンパク質である。コラーゲンは、生体における種々の結合組織に、力学的な強度を与えるのに役立っており、腱の主成分はコラーゲン繊維がきちんとすきまなく配列したもので、非常に強い力に耐える。また、皮膚においては、真皮の乾燥重量のうち約70%をコラーゲンが占めているといわれ、皮膚の弾力性や柔軟性を維持するのに重要な役割を果たしている。また、コラーゲンがそれに接する細胞に対して、増殖、分化シグナルを与えるための情報伝達の働きも担っていることがわかってきている。コラーゲンには種々のタイプが存在することが知られており、30種以上のタイプが報告されている。中でもコラーゲンの線維性を構成する基本のタイプがI型コラーゲンであり、生体の主要構成成分である。脊椎動物では85%〜90%と最も大量に存在するコラーゲンであり、骨に大量に含まれ、骨に弾力性を持たせる働きをしている。また皮膚の真皮にも非常に多く、I型コラーゲンの太い線維によって皮膚の強さを生み出す働きがある。
近年、皮膚の弾力性や、シワの改善を目的としてコラーゲンやコラーゲンの加水分解物を経口摂取することが行われており、「美容ドリンク」や「美肌飲料」などの名称でコラーゲンやコラーゲンの加水分解物を含む飲料が市販されている。これらの飲料は、1回あたりコラーゲン換算で900〜10000mgを摂取することが効果的であるといわれている。
経口摂取したコラーゲンやコラーゲンペプチドがどのような作用機序で皮膚の弾力性やシワの改善に働くのか、詳細な機構は明らかになっていないが、一部のコラーゲンペプチドが、コラーゲンを経口摂取すると血液中に出現することが知られている。そしてそのコラーゲンペプチドが線維芽細胞のI型コラーゲンの産生を促進することも知られている。
Collagen is a protein secreted extracellularly from fibroblasts. Collagen helps to give mechanical strength to various connective tissues in the living body, and the main component of the tendon is a neat arrangement of collagen fibers, which withstands a very strong force. In the skin, collagen is said to account for about 70% of the dry weight of the dermis, and plays an important role in maintaining the elasticity and flexibility of the skin. In addition, it is becoming clear that collagen also plays a role in transmitting information to give proliferation and differentiation signals to cells in contact with it. It is known that there are various types of collagen, and more than 30 types have been reported. Among them, the basic type that constitutes the fibrosis of collagen is type I collagen, which is a major constituent of the living body. Collagen, which is the most abundant in vertebrates at 85% to 90%, is contained in a large amount in bones and functions to make bones elastic. It is also very abundant in the dermis of the skin, and has the function of producing the strength of the skin by the thick fibers of type I collagen.
In recent years, collagen and collagen hydrolysates have been orally ingested for the purpose of improving skin elasticity and wrinkles, and collagen and collagen hydrolyzate under the names such as "beauty drink" and "skin-beautifying drink". Beverages containing decomposition products are commercially available. It is said that it is effective to ingest 900 to 10,000 mg of these beverages in terms of collagen at one time.
The detailed mechanism of the mechanism of action of orally ingested collagen and collagen peptide to improve skin elasticity and wrinkles has not been clarified, but some collagen peptides are used when collagen is ingested orally. It is known to appear in blood. It is also known that the collagen peptide promotes the production of type I collagen in fibroblasts.
特許文献1には、コラーゲンをコラゲナーゼで酵素分解した際に得られるGly−Pro−Hypの構造を有するトリペプチド(コラーゲントリペプチド)が生体コラーゲン合成促進作用を有し、これを含むコラーゲン加水分解物をコラーゲン合成促進剤として利用する技術が記載されている。
特許文献2には、前記のコラーゲントリペプチドとフラボノイドの一種であるシリマリンとリンゴ抽出物が、コラーゲンと線維芽細胞を含むコラーゲンゲルを収縮させ、シワ改善に用いることができることが記載されている。
特許文献3には、Gly−Pro−Hyp、Gly−His−Lys、Lys−Thr−Thr−Lys−Ser、またはGly−Glu−Pro−Argの構造を有するコラーゲン由来のペプチドがシリビンと相乗的にI型コラーゲンの産生を促進することが記載されている。
特許文献4では、コラーゲンを経口摂取した直後に血液中に出現する複数のトリペプチド又はジペプチドを合成して、Ala−Hyp−Gly、Pro−Hyp−Gly、Pro−Hyp、Leu−Hyp、Ala−Hypのジペプチドまたはトリペプチドが培養マウス線維芽細胞に対してコラーゲン合成を促進することを確認して、その結果に基づき、皮膚コラーゲン産生促進剤として利用することを提案している。
特許文献5にはGly−Pro、Pro−Gly、Pro−Hyp、Hyp−Gly、Gly−Hypのいずれかの配列を有するジペプチドを有効成分とするコラーゲン産生促進剤が記載されている。
このように、これまでの研究開発から、コラーゲンタンパク質の加水分解物やコラーゲンペプチド、アミノ酸など多くの物質がコラーゲン産生促進作用を有することが明らかとなっており、引き続き有用な物質の探索が行われている。
In Patent Document 1, a tripeptide (collagen tripeptide) having a Gly-Pro-Hyp structure obtained when collagen is enzymatically decomposed with collagenase has a biological collagen synthesis promoting action, and a collagen hydrolyzate containing the same. Is described as a technique for utilizing as a collagen synthesis promoter.
Patent Document 2 describes that the above-mentioned collagen tripeptide and silymarin and apple extract, which are one of flavonoids, can be used for improving wrinkles by contracting a collagen gel containing collagen and fibroblasts.
In Patent Document 3, a collagen-derived peptide having a structure of Gly-Pro-Hyp, Gly-His-Lys, Lys-Thr-Thr-Lys-Ser, or Gly-Glu-Pro-Arg synergistically with silybin. It has been described to promote the production of type I collagen.
In Patent Document 4, a plurality of tripeptides or dipeptides appearing in blood immediately after oral ingestion of collagen are synthesized to synthesize Ala-Hyp-Gly, Pro-Hyp-Gly, Pro-Hyp, Leu-Hyp, Ala-. It has been confirmed that a Hyp dipeptide or tripeptide promotes collagen synthesis in cultured mouse fibroblasts, and based on the results, it is proposed to use it as a skin collagen production promoter.
Patent Document 5 describes a collagen production promoter containing a dipeptide having a sequence of any one of Gly-Pro, Pro-Gly, Pro-Hyp, Hyp-Gly, and Gly-Hyp as an active ingredient.
As described above, from the research and development so far, it has been clarified that many substances such as collagen protein hydrolyzate, collagen peptide, and amino acid have a collagen production promoting action, and the search for useful substances is continued. ing.
一方、バラ科バラ属の植物の花弁又はつぼみのエキスに様々な作用が見いだされている。そして、これを化粧品や健康食品に配合できることも知られている。特許文献6には、ドッグローズ、アポテカリーズローズ、スイートブライヤー、ダマスクバラ、セイヨウバラ及びハマナシから選ばれる少なくとも1種のバラ科バラ属の植物のつぼみ又は花弁を水、親水性有機溶媒又はこれらの混合液により抽出処理して得られた抽出物を有効成分とする抗菌作用組成物や飲食品が記載されている。
特許文献7には、特許文献6と同様の抽出物であって、ドッグローズ、アポテカリーズローズ、スイートブライヤー、ダマスクバラ、セイヨウバラ及びハマナシから選ばれる少なくとも1種のバラ科植物のつぼみ又は花弁を水、親水性有機溶媒又はこれらの混合液により抽出処理して得られた抽出物が記載されている。そして、この抽出物に抗インフルエンザウィルス作用を見いだし、これを有効成分とする抗インフルエンザウィルス剤及びこれを配合した飲食品の発明が記載されている。
On the other hand, various actions have been found in the extracts of petals or buds of plants belonging to the genus Rosa in the family Rosaceae. It is also known that this can be incorporated into cosmetics and health foods. Patent Document 6 describes the buds or petals of at least one Rosaceae plant of the Rosaceae genus selected from dog rose, apotecary rose, sweet-brier, damask rose, rose and rose, water, hydrophilic organic solvent or these. The antibacterial action composition and food and drink containing the extract obtained by the extraction treatment with the mixed solution of the above as an active ingredient are described.
Patent Document 7 is an extract similar to Patent Document 6, and is a bud or petal of at least one Rosaceae plant selected from dog rose, apotecary rose, sweet briar, damask rose, rose rose and hamanashi. Is described as an extract obtained by extracting the mixture with water, a hydrophilic organic solvent or a mixture thereof. Then, an anti-influenza virus action is found in this extract, and an invention of an anti-influenza virus agent containing the same as an active ingredient and a food or drink containing the same is described.
本発明者らは、コラーゲンペプチドのコラーゲン産生促進機能の増強に注目している。そしてコラーゲンペプチドにバラツボミエキスを併用するとコラーゲンペプチドのコラーゲン産生能が向上することをすでに確認している。
本発明は、コラーゲンペプチドに含有されているトリペプチドであるGly−Pro−Hyp(以下「GPO」)及びGly−Pro−Ala(以下「GPA」)とバラ科バラ属の植物の花弁及び/またはつぼみのエキスを併用すると、極めて強いコラーゲン産生促進作用を発揮することを見出したことからなされたものである。
すなわち、本発明は、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとトリペプチドであるGPO及びGPAを含有する新規な組成物を提供することを課題とする。
The present inventors have focused on enhancing the collagen production promoting function of collagen peptides. It has already been confirmed that the collagen-producing ability of collagen peptide is improved by using rose tsubomi extract in combination with collagen peptide.
The present invention relates to the tripeptides Gly-Pro-Hyp (hereinafter "GPO") and Gly-Pro-Ala (hereinafter "GPA") contained in collagen peptide, and the petals and / or petals of plants belonging to the genus Rosaceae. It was made because it was found that when the bud extract is used in combination, it exerts an extremely strong collagen production promoting effect.
That is, it is an object of the present invention to provide a novel composition containing an extract of petals and / or buds of a plant belonging to the genus Rosa in the family Rosaceae and tripeptides GPO and GPA.
本発明の主な構成は、次のとおりである。
(1) バラ科バラ属の植物の花弁及び/又はつぼみのエキスと、Gly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドを有効成分として含有するコラーゲン産生促進用組成物。
(2)バラ科バラ属の植物の花弁及び/又はつぼみのエキス1質量部あたりGly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドをあわせて1〜200質量部含有する(1)に記載の組成物。
(3)バラ科バラ属の植物が、ガリカローズ、ドッグローズ、アポテカリーズローズ、スイートブライヤー、ダマスクバラ、セイヨウバラ及びハマナシから選ばれる1種以上である(1)又は(2)に記載の組成物。
(4)バラ科バラ属の植物の花弁及び/又はつぼみのエキスが水、親水性有機溶媒又はこれらの混合液により抽出処理して得られたエキスである(1)〜(3)のいずれかに記載の組成物。
The main configuration of the present invention is as follows.
(1) A composition for promoting collagen production containing an extract of petals and / or buds of a plant belonging to the genus Rosa in the family Rosaceae and two types of tripeptides having the sequences of Gly-Pro-Hyp and Gly-Pro-Ala as active ingredients. Stuff.
(2) 1 to 200 parts by mass of two types of tripeptides having the sequences of Gly-Pro-Hyp and Gly-Pro-Ala per 1 part by mass of the extract of petals and / or buds of plants of the genus Rosaceae. The composition according to (1).
(3) The composition according to (1) or (2), wherein the plant of the genus Rosa in the family Rosaceae is one or more species selected from Galica rose, dog rose, apotecary rose, sweet briar, damask rose, rose rose and hamanashi. Stuff.
(4) Any of (1) to (3) obtained by extracting the petal and / or bud extract of a plant belonging to the genus Rosa in the family Rosaceae with water, a hydrophilic organic solvent or a mixture thereof. The composition according to.
本発明の組成物は、生体コラーゲン産生を促進する作用を有している。そして本発明の組成物は、バラ科バラ属の植物の花弁及び/又はつぼみのエキスの示すコラーゲン産生促進作用及び、Gly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドの示すコラーゲン産生促進作用が相乗的に作用し、両者の示すコラーゲン産生促進作用をはるかに超えた高いコラーゲン産生促進作用を発揮する。
またバラ科バラ属の植物の花弁及び/又はつぼみのエキスの有する抗菌性や抗ウイルス作用をあわせ持つため、感染症の防御や、感染予後体力回復のための飲食品としても使用可能である。さらにまた、本発明の組成物は、原料とする成分の食経験が長く、安全性が確認されているため、飲食品として経口で摂取することができる。
The composition of the present invention has an action of promoting the production of biological collagen. The composition of the present invention is composed of two types of tripeptides having a collagen production promoting action exhibited by an extract of petals and / or buds of a plant belonging to the genus Rosaceae, and a sequence of Gly-Pro-Hyp and Gly-Pro-Ala. The collagen production promoting action shown in the above acts synergistically, and exerts a high collagen production promoting action far exceeding the collagen production promoting action shown by both.
In addition, since it also has antibacterial and antiviral effects of the petals and / or bud extracts of plants belonging to the genus Rosaceae, it can be used as a food or drink for protection against infectious diseases and recovery of prognosis and physical strength. Furthermore, the composition of the present invention can be orally ingested as a food or drink because the ingredients used as raw materials have a long eating experience and their safety has been confirmed.
本発明は、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとトリペプチドを含有するコラーゲン産生促進用組成物に関する。
本発明の組成物について説明する。
バラ科バラ属の植物の花弁及び/又はつぼみは、どのような品種から採取したものでもかまわないが、園芸種として大量に栽培されているものが産業上好ましい。このようなものとして特にガリカローズ(Rosa gallica)、ドッグローズ(Rosa canina)、アポテカリーズローズ(Rosa gallica officinalis)、スイートブライヤー(Rosa rubiginosa)、ダマスクバラ(Rosa damascena trigintipetala)、セイヨウバラ(Rosa centifolia)及びハマナシ(Rosa rugosarubra)が好ましい。
The present invention relates to a collagen production promoting composition containing an extract of petals and / or buds of a plant belonging to the genus Rosaceae and a tripeptide.
The composition of the present invention will be described.
The petals and / or buds of plants belonging to the genus Rosa in the Rosaceae family may be collected from any variety, but those cultivated in large quantities as horticultural species are industrially preferable. These include, in particular, Rosa gallica, dog rose (Rosa canina), apotecalis rose (Rosa gallica officinalis), sweet briginosa, damask rose (Rosa dasai rose), damask rose (Rosa dasai). And hamanashi (Rosa rugosarubra) are preferred.
例えば、バラ科バラ属の植物の花弁又はつぼみを生のまま又は乾燥した後、そのまま又は粗砕機を用い粉砕して溶媒抽出に供することにより得ることができる。抽出に用いる溶媒としては、水又は親水性有機溶媒及びこれらの混合液を室温乃至溶媒の沸点以下の温度で用いることが好ましい。具体的には、メタノール、エタノール等の低級アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール等の炭素数2〜4の多価アルコール、及びこれら親水性有機溶媒と水との混合溶媒などを用いることができる。なお、水と親水性有機溶媒との混合系溶媒を使用する場合には、低級アルコールの場合は水10質量部に対して1〜90質量部、低級脂肪族ケトンの場合は水10質量部に対して1〜40質量部、多価アルコールの場合は水10質量部に対して10〜90質量部添加することが好ましい。 For example, it can be obtained by raw or drying the petals or buds of a plant belonging to the genus Rosa in the family Rosaceae, and then pulverizing the plants as they are or using a coarse crusher for solvent extraction. As the solvent used for extraction, it is preferable to use water or a hydrophilic organic solvent and a mixed solution thereof at a temperature of room temperature to a temperature equal to or lower than the boiling point of the solvent. Specifically, lower alcohols such as methanol and ethanol; lower aliphatic ketones such as acetone and methyl ethyl ketone; polyhydric alcohols having 2 to 4 carbon atoms such as 1,3-butylene glycol and propylene glycol, and these hydrophilic organic solvents. A mixed solvent of water and water can be used. When a mixed solvent of water and a hydrophilic organic solvent is used, the amount of lower alcohol is 1 to 90 parts by mass with respect to 10 parts by mass of water, and the amount of lower aliphatic ketone is 10 parts by mass of water. On the other hand, it is preferable to add 1 to 40 parts by mass, and in the case of polyhydric alcohol, 10 to 90 parts by mass with respect to 10 parts by mass of water.
この場合、抽出処理は、室温乃至還流加熱下で、任意の装置を用いて行うことができる。例えば、抽出溶媒を満たした処理槽にバラ科バラ属の植物のつぼみ(又は花弁)を投入し、必要に応じて時々攪拌しながら、30分〜2時間静置して可溶性成分を溶出した後、濾過して固形物を除去し、得られた抽出液から抽出溶媒を溜去し、乾燥することにより赤褐色のバラエキスが得られる。抽出条件は、抽出溶媒として水を用いた場合には、通常50〜90℃で30分〜2時間程度である。また、抽出溶媒として水とエタノールとの混合溶媒を用いた場合には、通常40〜80℃で30分〜2時間程度である。なお、溶媒で抽出することにより得られる抽出液は、抽出溶媒が安全性の高いものであればそのまま配合して本発明の有効成分として用いることができる。特許文献6には具体的な製造方法が開示されており、これにしたがって本発明に適したエキスを得ることができる。 In this case, the extraction process can be carried out at room temperature or under reflux heating using any device. For example, the buds (or petals) of plants belonging to the genus Rosaceae are put into a treatment tank filled with an extraction solvent, and the soluble components are eluted by allowing them to stand for 30 minutes to 2 hours with occasional stirring as needed. , The solid matter is removed by filtration, the extraction solvent is distilled off from the obtained extract, and the extract is dried to obtain a reddish brown rose extract. When water is used as the extraction solvent, the extraction conditions are usually about 30 minutes to 2 hours at 50 to 90 ° C. When a mixed solvent of water and ethanol is used as the extraction solvent, it is usually about 30 minutes to 2 hours at 40 to 80 ° C. The extract obtained by extracting with a solvent can be used as an active ingredient of the present invention by blending it as it is as long as the extraction solvent has high safety. Patent Document 6 discloses a specific production method, and an extract suitable for the present invention can be obtained according to this.
このようにして得られるバラ科バラ属の植物のエキスは、原料に由来する好ましい風味を有しており、そのまま本発明に利用可能であるが、必要に応じて、脱色等を目的とする精製を施し、配合用途に応じて、アルコールその他の有機溶剤の溶液又は水溶液の形として利用することができる。 The extract of the Rosaceae plant of the Rosaceae family thus obtained has a preferable flavor derived from the raw material and can be used as it is in the present invention, but if necessary, it is purified for the purpose of decolorization or the like. It can be used as a solution of alcohol or other organic solvent or in the form of an aqueous solution, depending on the compounding application.
本発明に用いるバラ科バラ属の植物のエキスは、必要によりデキストリンやシクロデキストリンを添加して、噴霧乾燥などの乾燥手段で粉末化することもできる。
本発明に用いるバラ科バラ属の植物のエキスは、市販されているものを使用することができる。本発明に適した、バラのつぼみのエキスの噴霧乾燥品である丸善製薬株式会社製の「ローズバッツエキスパウダーMF」を例示できる。
本発明に用いるバラ科バラ属の植物エキスは、ポリフェノールとして5質量%以上含有し、好ましくは10〜80質量%、特に好ましくは10〜20質量%含有するものである。
なお、本発明に用いるバラ科バラ属の植物のエキス量は、植物抽出物由来の固形分相当量を指す。
The extract of a plant belonging to the genus Rosaceae used in the present invention can be pulverized by a drying means such as spray drying by adding dextrin or cyclodextrin, if necessary.
As the extract of the plant of the genus Rosa in the family Rosaceae used in the present invention, a commercially available extract can be used. An example is “Rose Butts Extract Powder MF” manufactured by Maruzen Pharmaceuticals Co., Ltd., which is a spray-dried rose bud extract suitable for the present invention.
The plant extract of the genus Rosaceae used in the present invention contains 5% by mass or more of polyphenol, preferably 10 to 80% by mass, and particularly preferably 10 to 20% by mass.
The amount of the extract of a plant belonging to the genus Rosaceae used in the present invention refers to the amount equivalent to the solid content derived from the plant extract.
本発明に用いるトリペプチドは、コラーゲンの酵素加水分解によって得られるコラーゲンペプチド中に含有されているトリペプチドが好ましく、豚、ウシなどの動物由来、魚由来のいずれも使用可能である。また、合成品であっても良い。
本発明のトリペプチドのアミノ酸配列は、Gly−Pro−Hyp及びGly−Pro−Alaの両成分を含有する。
また、GPO:GPAの比率が1:1〜3:1であるものが好ましいがこの限りではない。
The tripeptide used in the present invention is preferably a tripeptide contained in a collagen peptide obtained by enzymatic hydrolysis of collagen, and any animal-derived tripeptide such as pig or cow, or fish-derived tripeptide can be used. Moreover, it may be a synthetic product.
The amino acid sequence of the tripeptide of the present invention contains both Gly-Pro-Hyp and Gly-Pro-Ala components.
Further, it is preferable that the ratio of GPO: GPA is 1: 1 to 1-3: 1, but this is not the case.
本発明にあっては、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとトリペプチドの相乗作用によってコラーゲン産生を促進する。このような相乗効果を得るためには、バラ科バラ属の植物の花弁及び/又はつぼみのエキスとコラーゲントリペプチド(GPO及びGPAの合計)の配合比は、バラ科バラ属の植物の花弁及び/又はつぼみのエキス1質量部に対し1〜300質量部、好ましくは1〜200質量部、特に好ましくは5〜150質量部を含有する組成物とする。 In the present invention, collagen production is promoted by the synergistic action of the petal and / or bud extract of a plant belonging to the genus Rosa in the family Rosaceae and a tripeptide. In order to obtain such a synergistic effect, the blending ratio of the petal and / or bud extract of the Rosaceae plant and the collagen tripeptide (total of GPO and GPA) should be adjusted to the petals and / or bud plant petals and / Or a composition containing 1 to 300 parts by mass, preferably 1 to 200 parts by mass, and particularly preferably 5 to 150 parts by mass with respect to 1 part by mass of the bud extract.
この組成物を飲食品に添加する場合、 添加量は、0.01質量%以上、好ましくは0.5〜95質量%、特に好ましくは5〜90質量%である。医薬品とする場合、症状及び対象とする年齢や、体重、投与する剤形によって異なるため一義的に配合量を決定できない。 When this composition is added to foods and drinks, the amount added is 0.01% by mass or more, preferably 0.5 to 95% by mass, and particularly preferably 5 to 90% by mass. In the case of a drug, the amount to be blended cannot be uniquely determined because it depends on the symptom, the target age, the body weight, and the dosage form to be administered.
食品としては、通常の食品の他、栄養補助食品、機能性食品、健康食品、特定保健用食品等として、例えば、錠剤、カプセル、パウダー等のような形態が好ましい。その他、ジュースのような飲料、ゼリーに配合することもできる。 As the food, in addition to ordinary foods, nutritional supplements, functional foods, health foods, foods for specified health uses and the like, for example, tablets, capsules, powders and the like are preferable. In addition, it can be added to beverages such as juice and jelly.
医薬品用途において、投与に関しては、有効成分を経口投与、非経口摂取の場合、直腸内投与、注射等の投与方法に適した固体又は液体の医薬用無毒性担体と混合して、慣用の医薬製剤の形態で投与することができる。形態としては、例えば、粉末、散剤、顆粒、錠剤、カプセル等の固形剤、溶液剤、懸濁剤、乳剤等の液剤、凍結乾燥製剤等が挙げられる。これらの製剤は常套手段により調製することが可能である。上記の医薬品用担体としては、例えば、グルコース、乳糖、ショ糖、澱粉、マンニトール、デキストリン、脂肪酸グリセリド、ポリエチレングリコール、ヒドロキシエチレンデンプン、エチレングリコール、ポリオキシエチレンソルビタン脂肪酸エステル、アミノ酸、ゼラチン、アルブミン、水、生理食塩水等が挙げられる。必要に応じて、安定化剤、湿潤剤、乳化剤、結合剤、等張化剤等の添加剤を適宜添加することも可能である。 In pharmaceutical applications, the active ingredient is mixed with a solid or liquid medicinal non-toxic carrier suitable for administration methods such as rectal administration and injection in the case of oral administration or parenteral ingestion, and is used as a conventional pharmaceutical preparation. Can be administered in the form of. Examples of the form include solid preparations such as powders, powders, granules, tablets and capsules, liquid preparations such as solutions, suspensions and emulsions, and freeze-dried preparations. These formulations can be prepared by conventional means. Examples of the above-mentioned pharmaceutical carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethylene starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, albumin, and water. , Physiological saline and the like. If necessary, additives such as stabilizers, wetting agents, emulsifiers, binders and isotonic agents can be added as appropriate.
以下に本発明の組成物を用いたコラーゲン産生促進試験例及び比較試験例を示し、 本発明を具体的に説明する。
<1.トリペプチドGPO及びGPAの1:1混合物とバラつぼみエキスの併用効果確認試験>
(1)試験試料(サンプル)
バラ科バラ属の植物の花弁及び/又はつぼみのエキスとして、丸善製薬株式会社が販売
しているローズバッツエキスパウダーMFを用いた。またトリペプチドとして、Gly−Pro−Hyp(GPO)配列表配列番号1及びGly−Pro−Ala(GPA)配列表配列番号2を用いた。GPO、GPAは化学合成品の試薬純度のものを用いた。
Hereinafter, the present invention will be specifically described with reference to Examples of Collagen Production Promotion Test Examples and Comparative Test Examples Using the Composition of the Present Invention.
<1. Test to confirm the combined effect of a 1: 1 mixture of tripeptide GPO and GPA and rose bud extract>
(1) Test sample (sample)
Rose Butts Extract Powder MF sold by Maruzen Pharmaceuticals Co., Ltd. was used as an extract of petals and / or buds of plants belonging to the genus Rosa in the family Rosaceae. Further, as the tripeptide, Gly-Pro-Hyp (GPO) SEQ ID NO: 1 and Gly-Pro-Ala (GPA) SEQ ID NO: 2 were used. As GPO and GPA, those having reagent purity of chemically synthesized products were used.
(2)試験方法
1)使用細胞
正常ヒト皮膚線維芽細胞(NHDF:ロンザジャパン株式会社)
(2) Test method 1) Cells used Normal human skin fibroblasts (NHDF: Lonza Japan Co., Ltd.)
2)細胞培養
細胞は37℃、5%二酸化炭素、95%空気の条件下で培養を行った。培地は非働化したウシ胎児血清(FBS)(Hyclone laboratories)10%、penicilin−Streptmycin(Sigma Aldrich)1%を添加したダルベッコ改変イーグル培地(高グルコース含有、life technologies)を用いた。以降、この培地を「基礎培地」と表記する。通常培養には10cmまたは15cmディッシュを用い、継代時の細胞剥離には0.05%Trypsin−EDTA(Sigma Aldrich)を使用した。
2) Cell culture The cells were cultured under the conditions of 37 ° C., 5% carbon dioxide and 95% air. As the medium, Dulbecco's modified Eagle's medium (high glucose content, life technologies) supplemented with 10% of deactivated fetal bovine serum (FBS) (Hyclone laboratories) and 1% of penicillin-Streptomycin (Sigma-Aldrich) was used. Hereinafter, this medium will be referred to as "basal medium". A 10 cm or 15 cm dish was used for normal culture, and 0.05% Trypsin-EDTA (Sigma Aldrich) was used for cell detachment during passage.
(3)試験試料調製
試験試料は培地で溶解した。UVA照射前は基礎培地を用い、UVA照射後はFBS不含基礎培地を用いた。
試験試料の最終濃度
下記表1の濃度で試験を実施した。
(3) Preparation of test sample The test sample was dissolved in the medium. A basal medium was used before UVA irradiation, and an FBS-free basal medium was used after UVA irradiation.
Final Concentration of Test Sample The test was carried out at the concentration shown in Table 1 below.
(4)細胞の形態観察
添加による影響を確認するため形態観察を行った。形態観察には倒立型システム顕微鏡(OLYMPUS IX70)を用いて行った。
(4) Cell morphology observation A morphology observation was performed to confirm the effect of the addition. The morphology was observed using an inverted system microscope (OLYMPUS IX70).
(5)コラーゲン産生量の確認試験
24wellプレートに細胞を1×105cells/500μL/wellで播種した。1日前培養した後、評価試料を含む基礎培地500μLと交換して1日培養した。その後、ハンクス平衡塩溶液(HBSS、カルシウム・マグネシウム含有、フェノールレッド不含)500μLに置換し、蓋を取ったディッシュをUVA照射ランプの下に一列に置いて12J/cm2照射した(約132分)。照射後、HBSSを取り除き、サンプル入りのFBS不含基礎培地500μLと交換して2日間培養した。培地を回収し、−80℃中に保存した。培地回収後、ディッシュを500μLのリン酸緩衝生理食塩水で3回洗浄し、0.1Nの水酸化ナトリウム溶液200μLで懸濁し、細胞を回収した。
回収した培地は4℃、10,000×gで10分間遠心し、その上清中のI型コラーゲン量をCollagen Type I, Human, ELISA Kit(株式会社エーセル)を用いて測定した。細胞懸濁液は4℃、10,000×gで10分間遠心し、その上清中のタンパク量をPierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC)を用いて測定した。培地中のI型コラーゲン量は細胞タンパク量で補正した。また測定結果はコントロール(無添加)細胞のコラーゲン産生量に対する増加量を求め、増加率%を得た。なお結果は、3回試験した結果のコラーゲン産生増加率の平均値で示す。
(5) Confirmation test of collagen production The cells were seeded on a 24-well plate at 1 × 10 5 cells / 500 μL / well. After culturing one day before, the cells were replaced with 500 μL of the basal medium containing the evaluation sample and cultured for one day. Then, it was replaced with 500 μL of Hanks balanced salt solution (HBSS, calcium / magnesium-containing, phenol red-free), and the dishes with the lid removed were placed in a row under the UVA irradiation lamp and irradiated with 12 J / cm 2 (about 132 minutes). ). After irradiation, HBSS was removed, replaced with 500 μL of FBS-free basal medium containing a sample, and cultured for 2 days. Medium was collected and stored at -80 ° C. After collecting the medium, the dish was washed 3 times with 500 μL of phosphate buffered saline, suspended in 200 μL of 0.1 N sodium hydroxide solution, and the cells were recovered.
The collected medium was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of type I collagen in the supernatant was measured using Collagen Type I, Human, and ELISA Kit (Acel Co., Ltd.). The cell suspension was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of protein in the supernatant was measured using a Pierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC). The amount of type I collagen in the medium was corrected by the amount of cellular protein. As for the measurement result, the amount of increase with respect to the amount of collagen produced by the control (additive-free) cells was obtained, and the rate of increase was obtained. The results are shown by the average value of the collagen production increase rate as a result of the three tests.
(6)試験結果
試験結果を表1及び図1に示す。
(6) Test results The test results are shown in Table 1 and FIG.
表1及び図1から、バラつぼみエキスとGPOとGPA1:1混合トリペプチドの併用は顕著にコラーゲン産生を促進することが明らかとなった。 From Table 1 and FIG. 1, it was clarified that the combined use of rose bud extract, GPO and GPA 1: 1 mixed tripeptide significantly promotes collagen production.
またGPOとGPA1:1混合トリペプチドとバラつぼみエキス併用によるI型コラーゲン産生相乗効果の評価は、以下の基準で判定した。
相乗効果有りの評価:相加効果の理論値<実測値の場合を相乗効果「有」として判定した。
相加効果の理論値=(A/D−1)×100+(B/D−1)×100
実測値=(C/D−1)×100
A:バラつぼみエキス単独添加によるI型コラーゲン産生量
B:トリペプチド混合物添加によるI型コラーゲン産生量
C:バラつぼみエキスとトリペプチド混合物の併用によるI型コラーゲン産生量
D:コントロール群(無添加サンプル)のI型コラーゲン産生量
併用効果の判定表を、下記の表2に示す。
The evaluation of the synergistic effect of type I collagen production by the combined use of GPO and GPA 1: 1 mixed tripeptide and rose bud extract was judged according to the following criteria.
Evaluation of synergistic effect: The case where the theoretical value of the additive effect <the measured value was judged as having the synergistic effect.
Theoretical value of additive effect = (A / D-1) x 100 + (B / D-1) x 100
Measured value = (C / D-1) x 100
A: Type I collagen production by adding rose bud extract alone B: Type I collagen production by adding tripeptide mixture C: Type I collagen production by using rose bud extract and tripeptide mixture together D: Control group (sample without addition) ) I type collagen production amount The judgment table of the combined effect is shown in Table 2 below.
バラつぼみエキスとトリペプチドGPO、GPA混合物の併用により、I型コラーゲンの産生量が相乗的に上昇したことが確認できた。 It was confirmed that the combined use of the rose bud extract, the tripeptide GPO, and the GPA mixture synergistically increased the amount of type I collagen produced.
<2.トリペプチドGPO及びGPAの2:1混合物とバラつぼみエキスの併用効果確認試験>
(1)試験試料(サンプル)
バラ科バラ属の植物の花弁及び/又はつぼみのエキスとして、丸善製薬株式会社が販売
しているローズバッツエキスパウダーMFを用いた。またトリペプチドとして、試験1と同様にGPOとGPAを用いた。
<2. Test to confirm the combined effect of a 2: 1 mixture of tripeptide GPO and GPA and rose bud extract>
(1) Test sample (sample)
Rose Butts Extract Powder MF sold by Maruzen Pharmaceuticals Co., Ltd. was used as an extract of petals and / or buds of plants belonging to the genus Rosa in the family Rosaceae. As the tripeptide, GPO and GPA were used as in Test 1.
(2)試験方法
1)使用細胞
正常ヒト皮膚線維芽細胞(NHDF:ロンザジャパン株式会社)
(2) Test method 1) Cells used Normal human skin fibroblasts (NHDF: Lonza Japan Co., Ltd.)
2)細胞培養
細胞は37℃、5%二酸化炭素、95%空気の条件下で培養を行った。培地は非働化したウシ胎児血清(FBS)(Hyclone laboratories)10%、penicilin−Streptmycin(Sigma Aldrich)1%を添加したダルベッコ改変イーグル培地(高グルコース含有、life technologies)を用いた。通常培養には10cmまたは15cmディッシュを用い、継代時の細胞剥離には0.05%Trypsin−EDTA(Sigma Aldrich)を使用した。
2) Cell culture The cells were cultured under the conditions of 37 ° C., 5% carbon dioxide and 95% air. As the medium, Dulbecco's modified Eagle's medium (high glucose content, life technologies) supplemented with 10% of deactivated fetal bovine serum (FBS) (Hyclone laboratories) and 1% of penicillin-Streptomycin (Sigma-Aldrich) was used. A 10 cm or 15 cm dish was used for normal culture, and 0.05% Trypsin-EDTA (Sigma Aldrich) was used for cell detachment during passage.
(3)試験試料調製
試験試料は培地で溶解した。UVA照射前は基礎培地を用い、UVA照射後はFBS
不含基礎培地を用いた。
試験試料の最終濃度
下記表3の濃度で試験を実施した。
(3) Preparation of test sample The test sample was dissolved in the medium. Use basal medium before UVA irradiation and FBS after UVA irradiation
A basal-free medium was used.
Final Concentration of Test Sample The test was carried out at the concentrations shown in Table 3 below.
(4)細胞の形態観察
添加による影響を確認するため形態観察を行った。形態観察には倒立型システム顕微鏡(OLYMPUS IX70)を用いて行った。
(4) Cell morphology observation A morphology observation was performed to confirm the effect of the addition. The morphology was observed using an inverted system microscope (OLYMPUS IX70).
(5)コラーゲン産生量の確認試験
24wellプレートに細胞を1×105cells/500μL/wellで播種した。1日前培養した後、サンプル入り基礎培地500μLと交換して1日培養した。その後、ハンクス平衡塩溶液(HBSS、カルシウム・マグネシウム含有、フェノールレッド不含)500μLに置換し、蓋を取ったディッシュをUVA照射ランプの下に一列に置いて12J/cm2照射した(約132分)。照射後、HBSSを取り除き、サンプル入りのFBS不含基礎培地500μLと交換して2日間培養した。培地を回収し、−80℃中に保存した。培地回収後、ディッシュを500μLのリン酸緩衝生理食塩水で3回洗浄し、0.1Nの水酸化ナトリウム溶液200μLで懸濁し、細胞を回収した。
(5) Confirmation test of collagen production The cells were seeded on a 24-well plate at 1 × 10 5 cells / 500 μL / well. After culturing one day before, the cells were replaced with 500 μL of basal medium containing a sample and cultured for one day. Then, it was replaced with 500 μL of Hanks balanced salt solution (HBSS, calcium / magnesium-containing, phenol red-free), and the dishes with the lid removed were placed in a row under the UVA irradiation lamp and irradiated with 12 J / cm 2 (about 132 minutes). ). After irradiation, HBSS was removed, replaced with 500 μL of FBS-free basal medium containing a sample, and cultured for 2 days. Medium was collected and stored at -80 ° C. After collecting the medium, the dish was washed 3 times with 500 μL of phosphate buffered saline, suspended in 200 μL of 0.1 N sodium hydroxide solution, and the cells were recovered.
回収した培地は4℃、10,000×gで10分間遠心し、その上清中のI型コラーゲン量をCollagen Type I, Human, ELISA Kit(株式会社エーセル)を用いて測定した。細胞懸濁液は4℃、10,000×gで10分間遠心し、その上清中のタンパク量をPierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC)を用いて測定した。培地中のI型コラーゲン量は細胞タンパク量で補正した。また測定結果はコントロール(無添加)細胞のコラーゲン産生量に対する増加量を求め、増加率%を得た。なお結果は、3回試験した結果のコラーゲン産生増加率の平均値で示す。 The collected medium was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of type I collagen in the supernatant was measured using Collagen Type I, Human, and ELISA Kit (Acel Co., Ltd.). The cell suspension was centrifuged at 4 ° C. and 10,000 × g for 10 minutes, and the amount of protein in the supernatant was measured using a Pierce BCA Protein Assay kit (Thermo Fisher SCIENTIFIC). The amount of type I collagen in the medium was corrected by the amount of cellular protein. As for the measurement result, the amount of increase with respect to the amount of collagen produced by the control (additive-free) cells was obtained, and the rate of increase was obtained. The results are shown by the average value of the collagen production increase rate as a result of the three tests.
(6)試験結果
試験結果を表3及び図2に示す。
(6) Test results The test results are shown in Table 3 and FIG.
表3及び図2から、バラつぼみエキスとGPOとGPA2:1混合トリペプチドの併用は、コラーゲン産生を促進することが明らかとなった。 From Table 3 and FIG. 2, it was clarified that the combined use of rose bud extract, GPO and GPA 2: 1 mixed tripeptide promotes collagen production.
またGPOとGPA2:1混合トリペプチドとバラつぼみエキス併用によるI型コラーゲン産生相乗効果の評価は、以下の基準で判定した。
相乗効果有りの評価:相加効果の理論値<実測値の場合を相乗効果「有」として判定した。
相加効果の理論値=(A/D−1)×100+(B/D−1)×100
実測値=(C/D−1)×100
A:バラつぼみエキス単独添加によるI型コラーゲン産生量
B:トリペプチド混合物添加によるI型コラーゲン産生量
C:バラつぼみエキスとトリペプチド混合物の併用によるI型コラーゲン産生量
D:コントロール群(無添加サンプル)のI型コラーゲン産生量
併用効果の判定表を、下記の表4に示す。
The evaluation of the synergistic effect of type I collagen production by the combined use of GPO and GPA 2: 1 mixed tripeptide and rose bud extract was judged according to the following criteria.
Evaluation of synergistic effect: The case where the theoretical value of the additive effect <the measured value was judged as having the synergistic effect.
Theoretical value of additive effect = (A / D-1) x 100 + (B / D-1) x 100
Measured value = (C / D-1) x 100
A: Type I collagen production by adding rose bud extract alone B: Type I collagen production by adding tripeptide mixture C: Type I collagen production by using rose bud extract and tripeptide mixture together D: Control group (sample without addition) ) I type collagen production amount The judgment table of the combined effect is shown in Table 4 below.
バラつぼみエキスとトリペプチドGPO、GPA混合物の併用により、I型コラーゲンの産生量が相乗的に上昇したことが確認できた。 It was confirmed that the combined use of the rose bud extract, the tripeptide GPO, and the GPA mixture synergistically increased the amount of type I collagen produced.
<3.試験結果まとめ>
以上の試験1及び2から次の点が明らかとなった。
(1)バラつぼみエキスとGPO、GPAの混合物を併用すると生体のコラーゲン産生が相乗的に促進される。
(2)トリペプチドGPOとGPAの配合比率は、GPO:GPAの比率が1:1又は2:1の比率になるように混合して試験したが、いずれの場合もバラつぼみエキスと併用することでコラーゲン産生が相乗的に増加した。
<3. Test result summary>
The following points were clarified from the above tests 1 and 2.
(1) When a mixture of rose bud extract and GPO and GPA is used in combination, collagen production in a living body is synergistically promoted.
(2) The mixing ratio of tripeptide GPO and GPA was mixed and tested so that the ratio of GPO: GPA was 1: 1 or 2: 1. In either case, it should be used in combination with the rose bud extract. Collagen production increased synergistically.
参考製造例1
バラ科バラ属の植物のつぼみのエキスの製造例
アポテカリーズローズのつぼみ(Rosa gallica officinalis)300gに50質量%エタノールを2000mL加え、還流冷却器を付けて、80℃にて1時間抽出した後、濾紙で濾過して抽出液1を得た。また、抽出残渣に50重量%エタノール1500mLを加え、同様に還流冷却器を付けて、80℃にて1時間抽出した後、濾紙で濾過して抽出液2を得た。得られた抽出液1、2を合せて減圧下で濃縮、乾燥させて粉末エキス100gを得た(収率33.3%)。
Reference manufacturing example 1
Example of production of bud extract of a plant belonging to the genus Rosa of the Rosaceae family Add 2000 mL of 50% by mass ethanol to 300 g of buds (Rosa gallica officinalis), attach a reflux cooler, and extract at 80 ° C. for 1 hour. , The extract 1 was obtained by filtering with a filter paper. Further, 1500 mL of 50 wt% ethanol was added to the extraction residue, and the mixture was similarly attached with a reflux condenser, extracted at 80 ° C. for 1 hour, and then filtered through a filter paper to obtain an extract 2. The obtained extracts 1 and 2 were combined, concentrated under reduced pressure, and dried to obtain 100 g of a powder extract (yield 33.3%).
参考製造例2
バラ科バラ属の植物のつぼみのエキスの製造例
セイヨウバラのつぼみ(Rosa centifolia)300gに水2000mLを加え、90℃にて1時間抽出を行った後、濾紙にて濾過し、抽出液を得た。得られた抽出液を減圧下で濃縮、乾燥させて、製造例2の粉末エキス100gを得た(収率33.3%)。
Reference manufacturing example 2
Example of production of extract of buds of plants belonging to the genus Rosa in the family Rosaceae Add 2000 mL of water to 300 g of buds of roses (Rosa centifolia), extract at 90 ° C. for 1 hour, and then filter with filter paper to obtain an extract. It was. The obtained extract was concentrated under reduced pressure and dried to obtain 100 g of the powder extract of Production Example 2 (yield 33.3%).
Claims (2)
バラ科バラ属の植物の花弁及び/又はつぼみのエキス1質量部あたりGly−Pro−Hyp及びGly−Pro−Alaの配列を有する2種類のトリペプチドをあわせて1〜200質量部含有するコラーゲン産生促進用組成物。 And it rose species petals and / or buds of the plant extracts, met Gly-Pro-Hyp and Gly-Pro-Ala 2 types of collagen production promoting composition containing tripeptide as an active ingredient having the sequence of hand,
Collagen production containing 1 to 200 parts by mass of two types of tripeptides having the sequences of Gly-Pro-Hyp and Gly-Pro-Ala per 1 part by mass of the extract of petals and / or buds of plants of the genus Rosaceae. Acceleration composition .
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019125060A JP6777794B1 (en) | 2019-07-04 | 2019-07-04 | Composition for promoting collagen production |
CN202010619260.2A CN112167634B (en) | 2019-07-04 | 2020-07-01 | Composition for promoting collagen production |
TW109122398A TWI855104B (en) | 2019-07-04 | 2020-07-02 | Composition for acceleration of collagen production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019125060A JP6777794B1 (en) | 2019-07-04 | 2019-07-04 | Composition for promoting collagen production |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6777794B1 true JP6777794B1 (en) | 2020-10-28 |
JP2021011439A JP2021011439A (en) | 2021-02-04 |
Family
ID=72938129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019125060A Active JP6777794B1 (en) | 2019-07-04 | 2019-07-04 | Composition for promoting collagen production |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6777794B1 (en) |
CN (1) | CN112167634B (en) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2768621B1 (en) * | 1997-09-22 | 2000-04-07 | Oreal | USE OF AN EXTRACT OF AT LEAST ONE PLANT FROM THE ROSACEA FAMILY |
JP2003137807A (en) * | 2001-11-01 | 2003-05-14 | Miyagi Kagaku Kogyo Kk | Collagen-producing promoter, cosmetic, food and pharmaceutical containing the same and external preparation for preventing or improving dermatosis |
JP2003176219A (en) * | 2001-12-13 | 2003-06-24 | Ichimaru Pharcos Co Ltd | Collagen tripeptide-containing skin care preparation |
JP2003300818A (en) * | 2002-04-11 | 2003-10-21 | Harada:Kk | Cosmetic |
JP2004067552A (en) * | 2002-08-05 | 2004-03-04 | Naris Cosmetics Co Ltd | Collagen production promoter, and cosmetic containing the same |
JP4286513B2 (en) * | 2002-09-26 | 2009-07-01 | 株式会社ファンケル | Anti-aging composition |
JP4033877B2 (en) * | 2005-09-29 | 2008-01-16 | 株式会社ファンケル | Composition for promoting type I collagen production |
DE102009030351A1 (en) * | 2009-06-22 | 2010-12-23 | Gelita Ag | Composition for the treatment of degenerative joint diseases |
JP2011236156A (en) * | 2010-05-11 | 2011-11-24 | Pola Chemical Industries Inc | Collagen production promoter |
JP2012153614A (en) * | 2011-01-24 | 2012-08-16 | Unitika Ltd | Collagen production promoter |
WO2014062607A1 (en) * | 2012-10-15 | 2014-04-24 | Commercial Marine Biology Institute, Llc | Marine extract compositions and methods of use |
JP6448216B2 (en) * | 2014-05-02 | 2019-01-09 | 株式会社ニッピ | Method for preparing peptide composition, cell culture method, and peptide composition |
EP3146957A4 (en) * | 2014-05-19 | 2017-11-15 | Suntory Holdings Limited | Novel use of rose dye compound |
JP2016044150A (en) * | 2014-08-25 | 2016-04-04 | 富士フイルム株式会社 | Cosmetic |
CN105919836A (en) * | 2016-04-21 | 2016-09-07 | 珠海安和生化科技有限公司 | Anti-wrinkle composition added with plant essential oil and bioactive polypeptide and preparation method of anti-wrinkle composition |
CN107397716A (en) * | 2017-08-09 | 2017-11-28 | 陕西沐千惠商贸有限公司 | Promote cell turnover and can compact fair-skinned white product and preparation method |
-
2019
- 2019-07-04 JP JP2019125060A patent/JP6777794B1/en active Active
-
2020
- 2020-07-01 CN CN202010619260.2A patent/CN112167634B/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2021011439A (en) | 2021-02-04 |
CN112167634A (en) | 2021-01-05 |
CN112167634B (en) | 2024-03-01 |
TW202116346A (en) | 2021-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI594766B (en) | Collagen production promoter, hyaluronic acid production promoter, fibroblast proliferation promoter and anti-wrinkle agent | |
JP6606378B2 (en) | Collagen production promoter | |
WO2007148739A1 (en) | Cell activator, anti-aging agent and extracellular matrix production promoter derived from plant | |
JP4826696B2 (en) | Angiogenesis inhibitors | |
JP2010155820A (en) | Skin ameliorating agent, and vascular ameliorating agent, and pharmaceutical composition, food, feed and cosmetic comprising the same | |
JP2009067749A (en) | Matrix metalloprotease-1(mmp-1) inhibitor, matrix metalloprotease-2(mmp-2) inhibitor, estrogen-like action agent, profilaggrin production promoter, filaggrin production promoter, antiobese agent and cyclic amp phosphodiesterase activity inhibitor | |
KR101449763B1 (en) | Phaseolus vulgaris extracts, their use, and formulations containing them | |
JP5459826B2 (en) | Elastin production promoter and vascular endothelial cell growth promoter in dermal fibroblasts | |
JP6807535B2 (en) | Fibroblast growth factor | |
KR102511701B1 (en) | Functional collagen composition using collagen amino acid derived from Aurea Helianthus | |
JP6777794B1 (en) | Composition for promoting collagen production | |
JP6517546B2 (en) | Fibroblast cell proliferation promoter | |
JP2016056116A (en) | Composition for promoting collagen production | |
CN111466576A (en) | Food additive | |
JP6553790B1 (en) | Composition for promoting collagen production | |
JP2011225495A (en) | Vascular endothelial cell protecting agent, and pharmaceutical composition, food and feed containing the same | |
TWI855104B (en) | Composition for acceleration of collagen production | |
JP2003246741A (en) | Oral skin improver, food composition for skin improvement and skin improvement process | |
KR20200079215A (en) | Composition for Silkworm-collagen and manufacturing method thereof | |
JP6143218B2 (en) | Tendon and ligament function improving agent and pharmaceutical composition, food and feed containing the same | |
KR101839582B1 (en) | Composition for activating cell comprising bran extracts and Method of cell activation | |
JP6619530B2 (en) | Composition for inhibiting matrix metalloprotease production | |
KR101491902B1 (en) | Novel Peptide with collagenase inhibitory activity and use thereof | |
JP2019140996A (en) | Collagen production promoting agent | |
JP5063040B2 (en) | Angiogenesis inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200318 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200318 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200318 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200707 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201008 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6777794 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |